SCHEMBL600715

SCHEMBL600715

C[C@](N)(CCS)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600714 1.00
SCHEMBL27800247 1.00
SCHEMBL8687592 0.84 GGT1 (0.65)
SCHEMBL21663996 0.80
SCHEMBL62882 0.79
SCHEMBL64140 0.79
SCHEMBL8688802 0.79 ARG2 (0.72)
SCHEMBL62881 0.79
SCHEMBL1818554 0.77 GGT1 (0.58)
Hydrochloric Acid SCHEMBL1132932 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423075-B1 STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION DANA FARBER CANCER INST INC (US) 2024-04-03 EP disclosed
US-11945846-B2 Stapled intracellular-targeting antimicrobial peptides to treat infection DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-04-02 US disclosed
EP-3317294-B1 STABILIZED ANTI-MICROBIAL PEPTIDES DANA FARBER CANCER INST INC (US) 2023-03-15 EP disclosed
US-20200308236-A1 STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION DANA-FARBER CANCER INSTITUTE, INC. 2020-10-01 US disclosed
US-20200231638-A1 STABILIZED ANTI-MICROBIAL PEPTIDES DANA-FARBER CANCER INSTITUTE, INC. 2020-07-23 US disclosed
US-10464975-B2 Stabilized anti-microbial peptides DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-11-05 US disclosed
US-20190292224-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2019-09-26 US disclosed
US-10328117-B2 Bis-sulfhydryl macrocyclization systems AILERON THERAPEUTICS, INC. (US) 2019-06-25 US disclosed
US-20190185518-A9 WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 AILERON THERAPEUTICS, INC. 2019-06-20 US disclosed
US-10300109-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2019-05-28 US disclosed
CN-101636407-A Bimercapto macrocyclization system AILERON THERAPEUTICS INC (US) 2010-01-27 CN disclosed
US-20090326192-A1 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-12-31 US disclosed
WO-2009149214-A2 COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES AILERON THERAPEUTICS, INC. (US) 2009-12-10 WO disclosed
US-20090275519-A1 Therapeutic peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
WO-2009126292-A2 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-10-15 WO disclosed
EP-2094721-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS Aileron Therapeutics, Inc. (US) 2009-09-02 EP disclosed
WO-2009099677-A2 THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20090088553-A1 Bis-Sulfhydryl Macrocyclization Systems AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2009-04-02 US disclosed
US-20090047711-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS AILERON THERAPEUTICS, INC. (US) 2009-02-19 US disclosed
WO-2008076904-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS AILERON THERAPEUTICS, INC. (US) 2008-06-26 WO disclosed